Patent intelligence · US
US 9289514
Low density lipoprotein receptor-mediated siRNA delivery
Low density lipoprotein receptor-mediated siRNA delivery
Patent details — US 9289514
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2016
- Expiration
- Mar 17, 2036
- Applicant
- Arrowhead Research Corporation
- Claims
- 14
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K38/16
Quick answer
US 9289514 (Low density lipoprotein receptor-mediated siRNA delivery) is held by Arrowhead Research Corporation. Status: granted. Granted Mar 22, 2016. Expires Mar 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arrowhead Research Corporation
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K38/16, A61K47/64, A61K47/6425
More from Arrowhead Research Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted
Related coverage
Frequently asked questions
What is US patent 9289514?
US 9289514 (Low density lipoprotein receptor-mediated siRNA delivery) is held by Arrowhead Research Corporation. Status: granted. Granted Mar 22, 2016. Expires Mar 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9289514?
Arrowhead Research Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.
When does US 9289514 expire?
Our index shows an expiration date of Mar 17, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.